Bausch & Lomb Sold To Valeant Pharmaceuticals For $8.7 Billion

In the latest of more than a dozen acquisitions Valeant has made since it was created by a merger with Biovail SA in 2011, Valeant’s purchase of Bausch & Lomb will increase its eye care portfolio substantially.